錦欣生殖医療に関するコメント

Recent and previous insider purchases by Yang Dong suggest strong belief in Jinxin Fertility Group's value, even at higher prices. The absence of insider selling and significant insider ownership indicate alignment with shareholders, suggesting the share price may be undervalued.

Jinxin Fertility Group's falling ROCE is not encouraging, however, its reinvestment in growth could be promising for long-term stock performance if it succeeds. Nonetheless, other factors appear to be adversely affecting the company's prospects, as seen through the significant decline in stock price over recent years.

The absence of recent insider transactions doesn't diminish the company's prospects, given the insiders' significant shares. Their past activity underscores their confidence in the company's future.

Jinxin Fertility Group's low return on equity and drop in net income raise concerns over its reinvestment strategies. Despite positive industry projections, worry persists regarding the company's future due to its lackluster performance.